#### Check for updates

#### **OPEN ACCESS**

EDITED BY Gabriel Sandblom, Karolinska Institutet (KI), Sweden

REVIEWED BY

Francesco Pizza, PHD Aslnapoli2nord, Italy Peixin Li, Capital Medical University, China Mahdieh Golzarand, Shahid Beheshti University of Medical Sciences, Iran

\*CORRESPONDENCE Xia Ye wssd1990@163.com

<sup>†</sup>These authors have contributed equally to this work and share the first authorship

#### SPECIALTY SECTION

This article was submitted to Visceral Surgery, a section of the journal Frontiers in Surgery

RECEIVED 13 October 2022 ACCEPTED 21 December 2022 PUBLISHED 10 January 2023

#### CITATION

Zhou H, Jin Y, Dai S, Dai C and Ye X (2023) Effect of bariatric surgery on carotid intimamedia thickness: A meta-analysis based on observational studies. Front. Surg. 9:1068681. doi: 10.3389/fsurg.2022.1068681

#### COPYRIGHT

© 2023 Zhou, Jin, Dai, Dai and Ye. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Effect of bariatric surgery on carotid intima-media thickness: A meta-analysis based on observational studies

# Hui Zhou<sup>1†</sup>, Yangli Jin<sup>2†</sup>, Senjie Dai<sup>3</sup>, Chenglong Dai<sup>4</sup> and Xia Ye<sup>5\*</sup>

<sup>1</sup>Department of Ultrasound, The Affiliated Hospital of Ningbo University, LiHuiLi Hospital, Ningbo, China, <sup>2</sup>Department of Ultrasound, Ningbo Yinzhou No. 2 Hospital, Ningbo, China, <sup>3</sup>The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China, <sup>4</sup>School of Medical Imaging, Hangzhou Medical College, Hangzhou, China, <sup>5</sup>General Family Medicine, Ningbo Yinzhou No. 2 Hospital, Yinzhou district, ningbo, China

**Objective:** This meta-analysis aimed to investigate the effect of bariatric surgery on CIMT in people with obesity.

**Methods:** PubMed, Web of Science, Embase, and the Cochrane Library were searched for observational studies assessing the effect of bariatric surgery on CIMT from inception to August 2022. Mean difference (MD) and 95% confidence intervals were calculated to assess CIMT.

**Results:** A total of 23 studies, including 1,349 participants, were eligible to participate in this meta-analysis. The results revealed that CIMT was significantly decreased at 6 months, 12 months, and more than 18 months after bariatric surgery compared with baseline (6 months: MD = 0.09; P < 0.01; 12 months: MD = 0.12; P < 0.01; more than 18 months: MD = 0.14; P = 0.02). Meanwhile, laparoscopic Roux-en-Y gastric bypass (LRYGB) seemed to be more effective than laparoscopic sleeve gastrectomy (LSG) in lowering CIMT in terms of the type of surgery (LSG: MD = 0.11; P < 0.01; LRYGB: MD = 0.14; P < 0.01). Lastly, the benefits of bariatric surgery on CIMT was independent of gender (Male: MD = 0.06; P = 0.04; Female: MD = 0.08; P = 0.03).

**Conclusions:** Bariatric surgery is consistently effective in reducing CIMT in people with obesity.

#### KEYWORDS

bariatric surgery, carotid intima-Media thickness, obesity, weight loss, meta-analysis

# Introduction

The prevalence of obesity has increased worldwide over the last decades and has emerged as one of the greatest public health challenges (1). Obesity poses many health problems, and there is currently a huge body of clinical evidence linking obesity to cardiovascular diseases (2, 3). On the one hand, obesity can directly adapt to overweight by inducing changes in the cardiovascular structure and functions; on the other hand, obesity can induce cardiovascular risk factor conditions such as hyperlipidemia, hyperglycemia and insulin resistance (4-6).

Carotid intima-media thickness (CIMT), measured by ultrasonography, is a noninvasive, rapid, reproducible marker of subclinical atherosclerosis that is positively

associated with the risk of cardiovascular events and is widely considered to be an independent predictor of cardiovascular events (7, 8). Bariatric surgery has become a promising option for weight loss in situations where diet, lifestyle changes, and medical treatment do not produce the desired results (9, 10). At the same time, the benefits of bariatric surgery for weight loss as well as metabolic improvement have been established; nevertheless, its efficacy on CIMT remains to be validated. Currently, an increasing number of studies have explored the effect of bariatric surgery on CIMT in people with obesity. Therefore, this meta-analysis aimed to investigate the effect of bariatric surgery on alterations in CIMT in people with obesity by reviewing relevant studies.

# **Methods**

#### Search strategy

This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines (11). Electronic databases, including PubMed, Web of Science, Embase, and the Cochrane Library, were independently searched by two authors for articles on the effect of bariatric surgery on carotid intimal thickness. All included articles were published before August 2022. Keywords used for the search were as follows: "carotid intima-media thickness" OR " intima-media thickness" OR "carotid intimamedia" OR "intima-media" OR "CIMT" OR "IMT" AND "bariatric procedure" OR "weight loss procedure" OR "bariatric surgery" OR "GB" OR "gastric bypass" OR "laparoscopic Roux-en-Y gastric bypass" OR "laparoscopic sleeve gastrectomy" OR "sleeve gastrectomy" OR "LRYGB" OR "SG" OR "LSG". Furthermore, to avoid the omission of any additional qualifying articles, the references of the eligible articles were manually examined.

## Inclusion and exclusion criteria

Studies were included if they met the following criteria: (1) all participants were people with obesity; (2) participants underwent bariatric surgery; (3) the outcome was CIMT; (4) pre- and postoperative CIMT data were available.

Studies meeting any of the following criteria were excluded: (1) the article was not written in English; (2) no relevant or available data could be extracted; (3) in the event of duplicate or continuously updated publications, the latest edition was selected.

#### Quality assessment and data extraction

The Newcastle-Ottawa Scale (NOS) checklist was employed to evaluate the quality of the included observational studies

(OBSs) based on three aspects: patient selection, comparability of groups, and evaluation of outcomes (12). The checklist has a maximum score of 9 points, and articles scoring less than 6 points are considered low quality.

According to a predesigned data extraction form, two authors independently reviewed the included articles and extracted the relevant data. These data included study characteristics (author, year, country, follow-up time, and type of surgery) and patient characteristics (age, number of patients, body mass index (BMI), and levels of fasting plasma glucose, triglycerides, total cholesterol, high-density lipoprotein cholesterol (HDL-c), lowdensity lipoprotein cholesterol (LDL-c), etc.). Discrepancies were resolved by two reviewers in consultation with a third party.

### Statistical analysis

Statistical analysis of the data was performed using RevMan 5.3 software (The Cochrane Collaboration) and STATA 12.0. For some studies that provided only subgroup data but lacked combined results, we included subgroup data simultaneously for metaanalysis. Mean difference (MD) with 95% confidence intervals (CI) was used to compare CIMT before and after bariatric surgery. Considering the differences in surgical type and measurement site between studies, the random-effects model was applied for statistical analysis to improve the reliability of the results. Heterogeneity between the studies was determined using the Chi-square test and  $I^2$  statistics, and heterogeneity was considered significant when  $I^2$  was greater than 50%. Publication bias was assessed by using the Eggers' test. Meanwhile, sensitivity analyses were conducted to assess the reliability of the overall results. P < 0.05 was considered statistically significant.


## Results

### Study selection

According to the developed search strategy, 302 articles were retrieved from four databases, with no additional articles obtained through other channels. By reviewing the titles and abstracts, duplicated and irrelevant articles were excluded, yielding 45 articles for full-text review. A total of 22 studies were excluded due to nonbariatric surgery, duplicate reports, data unavailable and no relevant results, and 23 studies were finally included in this metaanalysis (13–35). The detailed PRISMA flowchart is displayed in Figure 1.

# Study characteristics and quality assessment

Table 1 summarizes the characteristics of the included studies. A total of 23 studies involving 1,349 participants who



had undergone bariatric surgery were included. These 23 studies were published between 2009 and 2022 and were conducted in several countries (9 in Turkey, 2 in Austria, 2 in Brazil, 2 in Spain, 1 in Italy, 1 in China, 1 in Chile, 1 in the United States, 1 in the Netherlands, 1 in India, 1 in Iran, and 1 in Egypt). The follow-up time of the included studies ranged from 3 months to 60 months, with the majority having a follow-up period of 6 to 12 months. In addition, laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB) were the primary surgeries performed for weight loss in these studies.

The detailed characteristics of the patients are presented in **Table 2**, including BMI, fasting blood glucose levels, total cholesterol levels, triglyceride levels, HDL-c levels, LDL-c levels, number of hypertensive patients, number of diabetic patients, number of hyperlipidemia patients, and number of

smokers, all of them being risk factors for cardiovascular diseases.

The NOS checklist was utilized to evaluate the quality of the included OBSs. All included studies scored greater than 6 points and were of high quality, as listed in **Supplementary Table S1**.

# CIMT

Fifteen studies assessed CIMT at 6 months after the surgery, and combined results revealed a significant decrease in CIMT compared to baseline, with significant heterogeneity among the studies (MD = 0.09; P < 0.01;  $I^2 = 88\%$ ; Figure 2). A total of 11 studies investigated CIMT at 12 months after surgery, and there was high heterogeneity among the studies. The pooled results showed that CIMT was decreased by 0.12 mm

Author	Year	Country	No. of patients	Age	Follow-up (months)	Type of surgery	
Altin	2018	Turkey	105	$43.61 \pm 12.24$	6	LSG	
Baykara	2018	Turkey	60	M:35.14 ± 11.30 F:38.86 ± 10.39	18	LSG	
Borzì	2020	Italy	17	39.8 ± 10.4	16 ± 8	LAGB; GBP; BDP	
Cekici	2021	Turkey	47	$38 \pm 10.48$	6	LSG	
Chen	2017	China	33	$47.7 \pm 11.6$	12	LRYGB	
Cobeta	2020	Spain	40	LSG:46 ± 9 LRYGB:51 ± 9	6	LSG; LRYGB	
Elitok	2020	Turkey	23	$40.4\pm5.6$	12	LRYGB	
Elkan	2022	Turkey	44	37.2 ± 10.9	6	LSG	
Garcia	2013	Chile	27	$43.5 \pm 8.8$	12	LSG; LRYGB	
Gómez-Martin	2020	Spain	40	LSG: 46 ± 9 LRYGB: 48 ± 9	12	LSG; LRYGB	
Habib	2009	United States	22 28	$44.5 \pm 2.4$ $44.8 \pm 1.8$	12 24	LRYGB	
Jonker	2018	Netherlands	166	42.5	12	LSG; LRYGB	
Kaul	2021	India	40	$40.8\pm10.7$	12	LSG; OAGB; LRYGB	
Kaya	2021	Turkey	71	37.6 ± 11.2	6	LSG	
Nabavi	2022	Iran	32	$38.18 \pm 1.18$	6	LRYGB	
Saleh	2012	Brazil	47	41	6-19	LRYGB	
Salman	2021	Egypt	120	$43.7\pm8.5$	12	LSG	
Sarmento	2009	Brazil	18	$44.1\pm9.8$	12	LRYGB	
Solmaz	2016	Turkey	48	LSG:42.96 ± 7.87 LGP:38.3 ± 9.88	6	LSG; LGP	
Sturm	2009	Austria	37	NA	18	LAGB; GBP	
Tschoner	2013	Austria	52	35.3	60	LAGB; GBP	
Yavuz	2021	Turkey	216	$42.3\pm10.1$	12	NA	
Yorulmaz	2016	Turkey	16	39.12 ± 10.63	4.6	LSG	

TABLE 1 Characteristics of all the studies included in the meta-analysis.

M: male; F: female; LSG: laparoscopic sleeve gastrectomy; LRYGB: laparoscopic Roux-en-Y gastric bypass; GBP: gastric by-passes; BDP: biliopancreatic diversions; OAGB: one anastomosis gastric bypass; LGP: laparoscopic gastric plication; LAGB: laparoscopic adjustable gastric banding; NA: not available.

from baseline, and the difference was statistically significant (MD = 0.12; P < 0.01;  $I^2 = 90\%$ ; **Figure 3**). Besides, four studies evaluated the longer-term effects of bariatric surgery on CIMT (follow-up of 18 months or more), and statistical analyses determined that CIMT was significantly lower (MD = 0.14; P = 0.02), as illustrated in **Figure 4**. Taken together, the benefits of decreased CIMT following bariatric surgery increased with the extension of follow-up time.

## Subgroup analysis

Subgroup analyses were performed to evaluate the impact of different surgical procedures on CIMT based on their distinct

characteristics. Eleven studies (n = 541) and nine studies (n = 798) investigated the effects of LSG and LRYGB on CIMT, respectively. Integrated data showed that both procedures significantly lowered CIMT in patients (LSG: MD = 0.11; P < 0.01; LRYGB: MD = 0.14; P < 0.01). At the same time, LRYGB seemed superior to LSG in reducing CIMT. The detailed results are displayed in Figure 5.

In terms of gender, 2 studies investigated the effect of bariatric surgery on CIMT in men, while 3 studies evaluated the effect of bariatric surgery on CIMT in women. The combined results showed that bariatric surgery significantly reduced CIMT in both genders (Male: MD = 0.06; P = 0.04; Female: MD = 0.08; P = 0.03). The findings of the subgroup analysis regarding gender are depicted in Figure 6.

Author	Year	BMI	FPG mg/dl	TC mg/dl	TGs mg/dl	HDL-c mg/dl	LDL-c mg/dl	ΗT	HL	DM	Somking
Altin	2018	$46.95 \pm 7.54$	123.76 ± 35.21	217.33 ± 41.83	126.35 ± 57.65	46.91 ± 9.63	$145.3\pm35.49$	47	78	28	26
Baykara	2018	$47.55 \pm 5.40$	103.71 ± 27.61	206.55 ± 30.57	$163.36 \pm 85.17$	39.41 ± 6.99	122.69 ± 29.92	NA	NA	NA	NA
Borzì	2020	$50.4 \pm 11.5$	89 ± 13	193 ± 40	$134 \pm 48$	$48 \pm 12$	$117 \pm 34$	4	NA	2	4
Cekici	2021	47.31 ± 6.10	$103.74\pm27.68$	193.26 ± 33.21	$233.45\pm74.44$	$37.72 \pm 12.70$	$108.43\pm28.76$	18	10	16	12
Chen	2017	30.9 ± 4.6	8.4 ± 2.4 mmol/L	4.9 ± 1.0 mmol/L	2.8 ± 2.5 mmol/L	1.0 ± 0.3 mmol/L	2.9 ± 1.0 mmol/L	18	NA	NA	NA
Cobeta	2020	LSG: 45.0 ± 6.9 LRYGB: 43.7 ± 7.2	$107 \pm 34$ $129 \pm 60$	$183 \pm 48$ $159 \pm 49$	$\begin{array}{c} 154 \pm 100 \\ 270 \pm 48 \end{array}$	$\begin{array}{c} 40\pm 6\\ 39\pm 9 \end{array}$	$117 \pm 36$ $82 \pm 29$	10 18	8 14	6 10	5 6
Elitok	2020	$52\pm 6.9$	106 ± 28	NA	$148\pm70$	$41 \pm 7$	$126 \pm 33$	NA	NA	NA	NA
Elkan	2022	$47.1 \pm 5.8$	$102 \pm 17$	193 ± 30	$247\pm69$	$35.1 \pm 11.2$	$107 \pm 28$	16	NA	15	11
Garcia	2013	$38 \pm 4$	$105 \pm 18$	$223\pm46$	$231 \pm 143$	$45\pm9$	$136 \pm 36$	NA	NA	NA	NA
Gómez-Martin	2020	LSG: 43.0 ± 4.0 LRYGB: 47.4 ± 6.4	$114.3 \pm 33.8$ $111.3 \pm 24.3$	NA	NA	NA	NA	NA	NA	NA	NA
Habib	2009	12M: 46.7 ± 1.6 24M: 47.2 ± 1.4	NA	$188 \pm 10$ $189 \pm 8$	$\begin{array}{c} 172\pm24\\ 168\pm15 \end{array}$	$\begin{array}{c} 45\pm2\\ 52\pm2\end{array}$	$\begin{array}{c} 110\pm8\\ 102\pm7 \end{array}$	NA	NA	NA	NA
Jonker	2018	$43.4\pm4.8$	NA	NA	NA	NA	NA	63	25	27	C:6 <i>P</i> :79
Kaul	2021	$45.9\pm6.5$	NA	171 ± 32.7	$124.2\pm45.8$	$41.5\pm8.2$	$103.8\pm29.7$	17	NA	15	8
Kaya	2021	$47.7 \pm 6.5$	104.6 ± 23.2	NA	$226 \pm 72$	$40.8\pm10.5$	$108 \pm 27$	23	NA	26	18
Nabavi	2022	43.66 ± 6.44	110.94 ± 45.59	171.62 ± 42.83	$150.94\pm81.82$	NA	NA	7	20	10	5
Saleh	2012	47.1 ± 5.5	94.7 ± 21.7	183.4 ± 37.7	148.6 ± 94.6	$40.4\pm9.7$	113.9 ± 29.2	29	11	NA	C:2 <i>P</i> :9
Salman	2021	43.8 ± 5.2	8.5 ± 3.52 mmol/L	5.48 ± 1.29 mmol/L	2.17 ± 0.52 mmol/L	1.17 ± 0.19 mmol/L	3.13 ± 1.08 mmol/L	48	35	49	NA
Sarmento	2009	$44.3 \pm 6.4$	97.9 ± 29.6	NA	145.7 ± 72.7	51.9 ± 15.7	108.5 ± 33.6	10	6	3	NA
Solmaz	2016	LSG: 44.84 ± 3.63 LGP: 45.39 ± 3.69	NA	$206.52 \pm 49.74$ $210.61 \pm 53.01$	190.88 ± 151.27 177.52 ± 100.14	$47.6 \pm 11.73$ $46.48 \pm 10.48$	$\begin{array}{c} 123.4 \pm 40.98 \\ 130.7 \pm 45.36 \end{array}$	NA	NA	NA	NA
Sturm	2009	42.42 + 3.98	98.2 + 11.5	194.5 ± 40.8	120 ± 58	49.4 ± 10.2	120.1 ± 34.9	NA	NA	NA	NA
Tschoner	2013	43.6 + 4.9	5.54 + 0.62 mmol/L	4.94 ± 0.91 mmol/L	1.24 ± 0.77 mmol/L	1.25 ± 0.29 mmol/L	3.04 ± 0.83 mmol/L	31	NA	NA	NA
Yavuz	2021	48.25 ± 7.09	109.70 ± 47.42	206.20 ± 42.61	156.90 ± 92.62	47.62 ± 11.64	129.90 ± 41.45	NA	NA	125	NA
Yorulmaz	2016	NA	NA	$209.12 \pm 48.71$	$153.00 \pm 61.05$	$45.125 \pm 6.80$	$209.12\pm48.71$	NA	NA	NA	NA

TABLE 2 Characteristics of the patients included in the study.

BMI: body mass index; FPG: fasting plasma glucose; TC: total cholesterol; TGs: triglycerides; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; HT: hyperlipidemia; DM: diabetes mellitus; M: months; C: current; P: past; NA: not available.

## Publication bias and sensitivity analysis

marginal impact on the overall effect, suggesting that the overall statistical results were stable.

Publication bias and sensitivity analyses were performed on 6- and 12-month studies of CIMT. The results of Eggers regression test showed no publication bias (6 months: P = 0.172; 12 months: P = 0.462). The specific results are delineated in **Supplementary Figures S1 and S2**. Individual studies were excluded one by one to assess the stability of the results. The results showed that individual studies had a

# Discussion


Obesity is strongly associated with adverse cardiovascular outcomes, and studies have established that CIMT is significantly thicker in people with obesity, with each 0.1 mm

	Ba	seline	9	Fo	ollow-up	)		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	I IV, Random, 95% CI
Altin 2018	0.74	0.13	105	0.67	0.11	105	6.4%	0.07 [0.04, 0.10]	
Baykara 2018	0.519	0.11	60	0.384	0.06	60	6.5%	0.14 [0.10, 0.17]	-
Cekici 2021	1.07	0.05	47	1	0.14	47	6.1%	0.07 [0.03, 0.11]	
Cobeta 2020	0.66	0.13	20	0.6	0.07	20	5.1%	0.06 [-0.00, 0.12]	
Cobeta 2020	0.65	0.11	20	0.59	0.06	20	5.6%	0.06 [0.01, 0.11]	
Elitok 2020	0.79	0.19	23	0.71	0.13	23	3.9%	0.08 [-0.01, 0.17]	
Elkan 2022	1.06	0.05	44	0.98	0.14	44	6.0%	0.08 [0.04, 0.12]	<del></del> -
Habib 2009	0.84	0.14	22	0.52	0.09	22	4.9%	0.32 [0.25, 0.39]	
Jonker 2018	0.619	0.11	128	0.622	0.11	116	6.6%	-0.00 [-0.03, 0.02]	+
Kaul 2021	0.58	0.09	40	0.54	0.08	40	6.3%	0.04 [0.00, 0.08]	
Kaya 2021	1.07	0.06	71	0.99	0.13	71	6.4%	0.08 [0.05, 0.11]	<del></del>
Nabavi 2022	0.53	0.06	32	0.5	0.08	32	6.4%	0.03 [-0.00, 0.06]	
Salman 2021	0.95	0.17	120	0.83	0.12	120	6.3%	0.12 [0.08, 0.16]	
Sarmento 2009	0.73	0.12	18	0.63	0.12	18	4.6%	0.10 [0.02, 0.18]	——
Solmaz 2016	0.688	0.09	25	0.52	0.05	25	6.2%	0.17 [0.13, 0.21]	
Solmaz 2016	0.619	0.07	23	0.52	0.058	23	6.3%	0.10 [0.06, 0.14]	
Yavuz 2021	0.58	0.12	216	0.49	0.1	62	6.5%	0.09 [0.06, 0.12]	-
Total (95% CI)			1014			848	100.0%	0.09 [0.06, 0.12]	•
Heterogeneity: Tau <sup>2</sup> =	0.00; Cł	ni² = 13	30.17, c	lf = 16 (	P < 0.00	0001); I	² = 88%		
Test for overall effect:	Z = 6.38	(P < (	0.00001	)					-0.5 -0.25 0 0.25 0.5 Favours [Baseline] Favours [Follow-up]

FIGURE 2

Forest plot of meta-analysis of CIMT at 6 months after bariatric surgery. (Cobeta 2020 and Solmaz 2016 respectively included two subsets of data for meta-analysis).

	В	aseline		Fo	ollow-up	)		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Baykara 2018	0.519	0.11	60	0.342	0.06	60	9.3%	0.18 [0.15, 0.21]	-
Chen 2017	0.59	0.097	33	0.539	0.099	33	8.8%	0.05 [0.00, 0.10]	_ <b>_</b> _
Elitok 2020	0.79	0.19	23	0.65	0.11	23	6.9%	0.14 [0.05, 0.23]	
Garcia 2013	0.578	0.14	27	0.487	0.09	27	8.2%	0.09 [0.03, 0.15]	
Gómez-Martin 2020	0.76	0.15	20	0.68	0.12	20	7.2%	0.08 [-0.00, 0.16]	
Gómez-Martin 2020	0.73	0.13	20	0.62	0.12	20	7.5%	0.11 [0.03, 0.19]	
Habib 2009	0.84	0.14	22	0.52	0.09	22	7.9%	0.32 [0.25, 0.39]	
Jonker 2018	0.619	0.11	128	0.587	0.1	111	9.4%	0.03 [0.01, 0.06]	-
Kaul 2021	0.58	0.09	40	0.52	0.1	40	9.0%	0.06 [0.02, 0.10]	
Salman 2021	0.95	0.17	120	0.77	0.1	120	9.2%	0.18 [0.14, 0.22]	
Sarmento 2009	0.73	0.12	18	0.6	0.12	18	7.5%	0.13 [0.05, 0.21]	
Yavuz 2021	0.58	0.12	216	0.46	0.11	41	9.1%	0.12 [0.08, 0.16]	
Total (95% CI)			727			535	100.0%	0.12 [0.08, 0.17]	•
Heterogeneity: Tau <sup>2</sup> =	0.01: Cł	ni² = 113	3.53. df	= 11 (P	< 0.000	001): l²	= 90%	• • •	+ + + +
Test for overall effect:				`					-0.5 -0.25 0 0.25 0.5 Favours [Baseline] Favours [Follow-up]
									· · · · · · · · · · · · · · · · · · ·



1.1.1 LSG   Altin 2018   Baykara 2018 0   Cekici 2021   Cobeta 2020   Elkan 2022   Garcia 2013 0	0.74 0.519 1.07 0.65 1.06	0.13 0.11 0.05	Total 105 60 47	0.67	<u>SD</u> 0.11		Weight	IV, Random, 95% C	I IV, Random, 95% CI
Altin 2018 Baykara 2018 0 Cekici 2021 Cobeta 2020 Elkan 2022 Garcia 2013 0	).519 1.07 0.65	0.11 0.05	60		0.11				
Baykara 2018 0 Cekici 2021 Cobeta 2020 Elkan 2022 Garcia 2013 0	).519 1.07 0.65	0.11 0.05	60		0.11				
Cekici 2021 Cobeta 2020 Elkan 2022 Garcia 2013 0	1.07 0.65	0.05		0.353		105	5.4%	0.07 [0.04, 0.10]	
Cobeta 2020 Elkan 2022 Garcia 2013 0	0.65		17	5.000	0.06	60	5.5%	0.17 [0.13, 0.20]	
Elkan 2022 Garcia 2013 0				1	0.14	47	5.2%	0.07 [0.03, 0.11]	
Garcia 2013 0	1.06	0.11	20	0.59	0.06	20	4.9%	0.06 [0.01, 0.11]	
		0.05	44	0.98	0.14	44	5.2%	0.08 [0.04, 0.12]	
Sómez-Martin 2020	).593	0.1	13	0.476	0.05	13	4.8%	0.12 [0.06, 0.18]	
	0.73	0.13	20	0.62	0.12	20	4.3%	0.11 [0.03, 0.19]	
	1.07	0.06	71	0.99	0.13	71	5.4%	0.08 [0.05, 0.11]	
	0.95	0.17	120	0.77	0.1	120	5.4%	0.18 [0.14, 0.22]	
	).688	0.09	25	0.52	0.05	25	5.3%	0.17 [0.13, 0.21]	
	0.67	0.22	16	0.54	0.11	16	3.2%	0.13 [0.01, 0.25]	· · · · · · · · · · · · · · · · · · ·
Subtotal (95% CI)			541			541	54.8%	0.11 [0.08, 0.14]	•
leterogeneity: Tau <sup>2</sup> = 0.0					< 0.0000	)1); l² =	81%		
est for overall effect: Z =	= 7.17	(P < 0.0	00001)						
.1.2 LRYGB									
	0.59	0 097	33	0.539	0 000	33	5.1%	0.05 [0.00, 0.10]	
	0.66	0.13	20	0.555	0.000	20	4.7%	0.06 [-0.00, 0.12]	
	0.79	0.19	23	0.65	0.07	23	4.0%	0.14 [0.05, 0.23]	
	0.765	0.17	14	0.497	0.1	14	3.6%	0.07 [-0.04, 0.17]	
	0.76	0.15	20	0.68	0.12	20	4.2%	0.08 [-0.00, 0.16]	
	0.84	0.14	22	0.52	0.09	22	4.6%	0.32 [0.25, 0.39]	
	0.86	0.21	28	0.5	0.11	28	4.1%	0.36 [0.27, 0.45]	
	0.53	0.06	32	0.5	0.08	32	5.4%	0.03 [-0.00, 0.06]	
	0.74	0.1	47	0.52	0.1	47	5.3%	0.22 [0.18, 0.26]	
	0.73	0.12	18	0.6	0.12	18	4.3%	0.13 [0.05, 0.21]	
Subtotal (95% CI)			257	2.0	<b>L</b>	257	45.2%	0.14 [0.07, 0.22]	•
leterogeneity: Tau <sup>2</sup> = 0.0	01; Chi	i² = 123	.40, df	= 9 (P <	< 0.0000	)1); l² =	93%		
est for overall effect: Z =				`					
otal (95% CI)			798			792	100.0%	0.13 [0.09, 0.16]	•
leterogeneity: Tau <sup>2</sup> = 0.0	10. Ch	2 - 175		- 20 /0	~ 0.000			0.10 [0.00, 0.10]	+ + + +
est for overall effect: Z =					~ 0.000	, r, r-	- 09 /0		-0.5 -0.25 0 0.25 0.
est for overall effect: Z =		•			- 0.41	12 - 00/			Favours [Baseline] Favours [Follow-up]
est for suburoup differen	nces: (	JII" – U	.09. 01	- 118 -	- 0.4 1).	i − 0%			

Forest plot of meta-analysis for CIMT by the type of surgery. (Cobeta 2020, Garcia 2013, Habib 2009, Gómez-Martin 2020 respectively included two subsets of data for meta-analysis).

	Da	iseline		Fo	llow-u	0		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
1.2.1 Male									
Cobeta 2020	0.66	0.13	20	0.6	0.07	20	11.5%	0.06 [-0.00, 0.12]	
Cobeta 2020	0.65	0.11	20	0.59	0.06	20	14.6%	0.06 [0.01, 0.11]	
Jonker 2018	0.675	0.1	38	0.622	0.11	38	17.9%	0.05 [0.01, 0.10]	
Subtotal (95% CI)			78			78	44.0%	0.06 [0.03, 0.09]	-
Heterogeneity: Tau <sup>2</sup> = 0	0.00; Cł	ni² = 0.	05, df =	= 2 (P =	0.98);	$I^2 = 0\%$	)		
Test for overall effect: 2	Z = 3.56	6 (P = 0	0.0004)						
1.2.2 Female									
Gómez-Martin 2020	0.73	0.13	20	0.62	0.12	20	8.6%	0.11 [0.03, 0.19]	
Gómez-Martin 2020	0.76	0.15	20	0.68	0.12	20	7.5%	0.08 [-0.00, 0.16]	
Jonker 2018	0.619	0.11	128	0.587	0.1	111	31.4%	0.03 [0.01, 0.06]	
Sarmento 2009	0.73	0.12	18	0.6	0.12	18	8.5%	0.13 [0.05, 0.21]	
Subtotal (95% CI)			186			169	56.0%	0.08 [0.03, 0.13]	
Heterogeneity: Tau <sup>2</sup> = 0	0.00; Cł	ni² = 8.	54, df =	= 3 (P =	0.04);	l² = 65	%		
Test for overall effect: 2	2 = 2.93	6 (P = 0	0.003)						
Fotal (95% CI)			264			247	100.0%	0.06 [0.04, 0.09]	◆
Heterogeneity: Tau <sup>2</sup> = 0	0.00; Cł	ni² = 8.	67, df =	= 6 (P =	0.19);	l² = 31	%		-0.2 -0.1 0 0.1 0.2
Test for overall effect: Z	z = 4.82	: (P < 0	.00001	)					-0.2 -0.1 0 0.1 0.2 Favours [Baseline] Favours [Follow-up]
Test for subaroup differ	ences:	Chi² =	0.52. c	lf = 1 (P	9 = 0.47	').  ² = (	0%		

increase in CIMT increasing the risk of myocardial infarction by 10%-15% and the risk of stroke by 10%-13% (36). Bariatric surgery is regarded as a safe and effective treatment for morbid obesity that can achieve weight loss by limiting gastric volume, regulating gastrointestinal hormones, and adjusting gut microbiota composition and function (37-39). Its positive effects on lipids, C-reactive protein, and other parameters have been corroborated. However, its effect on CIMT needs further exploration. Based on the included 23 studies, the results of this meta-analysis showed that CIMT continued to improve following bariatric surgery compared to baseline, signifying that bariatric surgery is an effective means to reduce CIMT in people with obesity. In addition, the results signaled that the benefits of bariatric surgery on CIMT increased with time. Subgroup analysis of the type of surgery demonstrated that both LRYGB and LSG were effective in reducing CIMT, while the former appeared to be more effective. By the way, the effect of bariatric surgery on CIMT was independent of gender.

The mechanism by which bariatric surgery reduces CIMT may be multifaceted. Firstly, patients lose weight and enhance their metabolism following bariatric surgery, thereby effectively improving blood lipids and subsequently decreasing CIMT (40). Secondly, the relief of complications such as hypertension can improve intimal injury and reduce blood lipid accumulation (41). Thirdly, there is a large body of evidence suggesting that bariatric surgery improves the inflammatory status of people with obesity, and can effectively regulate the levels of C-reactive protein, interleukin-6, adipokine, and other mediators, which are closely related to improvements in postoperative CIMT (42). Fourthly, fluctuations in the braingut endocrine axis after weight loss surgery can significantly modulate body metabolism and improve blood lipids and other parameters (43, 44). Finally, studies have shown that bariatric surgery can play a pivotal role in mediating coagulation and reducing the hypercoagulable state of blood vessels (45).

Significant improvements were noted, given that CIMT decreased by 0.09 mm, 0.12 mm, and 0.14 mm at 6 months, 12 months, and more than 18 months after the operation, respectively. From the numerical changes, it can be found that CIMT can continue to benefit after bariatric surgery. We speculate that this is inextricably linked to achieving longlasting and effective weight loss after bariatric surgery. Presently, bariatric surgery has been a very mature means of weight loss, coupled with psychological or behavioral intervention, patients with postoperative anxiety, depression, emotional eating and overeating less and less, patients with better overall compliance, less weight rebound, so that CIMT can continue to benefit. However, a study following up on patients for five years found that CIMT was comparable to baseline levels after five years (32). Notably, the baseline CIMT in this study was only 0.57 mm, which may be a limitation for further reduction of CIMT. Furthermore, the study included a small sample size and five-year follow-up data from 62 individuals. In a word, studies on the long-term effects of bariatric surgery on CIMT are limited, with a limited sample size and high heterogeneity. Long-term outcomes of CIMT following bariatric surgery should be further investigated in larger sample-size studies.

LSG and LRYGB are the most widely used procedures for weight loss. The former achieves weight loss by excising the greater curvature to limit gastric capacity, whereas the latter achieves weight loss by altering the route of food through the digestive tract. A subgroup analysis was performed to investigate the benefits of different surgical procedures, and the results exposed that LRYGB appeared to be associated with superior benefits in CIMT in people with obesity compared to LSG, which is contrary to previous findings. However, it should be noted that in Tannaz 's study, CIMT decreased 0.114 mm and 0.109 mm after LSG and LRYGB, respectively, with a difference of only 0.05 mm (46). Therefore, we believe it seems less rigorous to conclude directly that LSG was superior to LRYGB. A meta-analysis conducted by Hu et al. showed that LRYGB was more effective than LSG in comorbidity resolution in the short term (47). Likewise, a meta-analysis by Gu et al. involving 9,038 participants found that LRYGB was more effective in improving long-term complications and weight loss (48). Collectively, LRYGB had better outcomes in terms of weight reduction and improving comorbidities, both in the long-term and short-term, which we hypothesize may be a plausible explanation for the above results. Therefore, LRYGB may be a better option for weight loss patients with high cardiovascular risk factors.

Previous studies have shown significant gender disparities in weight loss and a higher incidence of carotid plaque formation in men than women. Therefore, the effect of bariatric surgery on CIMT must take gender into account. Physiologically, testosterone levels are higher in men, whereas estrogen levels are higher in women. The former is a key hormone and plays an essential role in fatty acid metabolism and glycemic control (**49**), whilst the latter exerts significant cardioprotective and anti-inflammatory effects and can prevent endothelial apoptosis and necrosis (50, 51). Besides, there are also differences in basal metabolism between the two genders. Psychologically, women have higher requirements for their stature management and a higher compliance rate after surgery. They can better adhere to the postoperative plan and control their dietary intake, which is crucial for preventing weight rebound. Based on the aforementioned factors, a subgroup analysis was performed regarding gender, and the results revealed that bariatric surgery had similar effects on CIMT improvement in both men and women.

The strengths of our study were a large population base and detailed subgroup analysis. In contrast to previous meta-analyses, we analyzed the effect of gender on the effect of bariatric surgery for the first time. Meanwhile, a more exact time node was

formulated in terms of follow-up time, and the results showed that CIMT had significantly decreased at 6 months and continued to benefit at 12 months and more than 18 months, indicating that the benefit of bariatric surgery for CIMT was durable. The limitations of the study should be considered. To begin, although the results of this study were statistically significant, they were highly heterogeneous and should be interpreted with caution. The sources of heterogeneity are manifold. Patients' inclusion criteria varied across studies, as did the degree of vascular abnormalities at baseline. At the same time, the different types of surgery are also sources of potential bias. However, subgroup analyses were performed to assess effect size across the type of surgery, and the study found that both LSG and LRYGB were effective in reducing CIMT. In addition, the site for measuring CIMT is also an important factor contributing to heterogeneity, and CIMT measured at different sites varies. It has been reported that the predilection sites for plaque formation are at the carotid bifurcation and the internal carotid artery, and measuring CIMT at these sites seems to provide a more accurate estimation of the benefits of bariatric surgery. Secondly, the small sample size of some studies lowered the accuracy of the results. Thirdly, the limited sample size restricted further subgroup analysis (e.g., age and BMI). Fourthly, it is unknown about the participants' postoperative treatment, which may affect the reliability of the results to some extent. Finally, the included studies were all observational studies and and inherently generated bias. Therefore, more comprehensive, high-quality studies are needed to validate our results.

# Conclusion

In conclusion, bariatric surgery reduced CIMT in people with obesity and had a sustained, gender-independent effect. Moreover, LRYGB may be more effective than LSG in lowering CIMT.

# Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

# References

1. Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. *Circ Res.* (2016) 118(11):1752–70. doi: 10.1161/CIRCRESAHA.115.306883

2. Haslam DW, James WP. Obesity. Lancet (London, England). (2005) 366 (9492):1197-209. doi: 10.1016/S0140-6736(05)67483-1

3. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American heart association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical

# Author contributions

All authors had read and approved the manuscript. All authors contributed to the article and approved the submitted version.

# Funding

This study was supported by the Natural Science Foundation of Ningbo, China (project No. 2018A610398), the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission, China, (project No. 2022KY343), and the Science and Technology Program for Public wellbeing of Ningbo, China (project No. 2022AS069).

# **Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

# Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg. 2022.1068681/full#supplementary-material.

activity, and metabolism. *Circulation.* (2006) 113(6):898–918. doi: 10.1161/CIRCULATIONAHA.106.171016

4. Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. *Metab: Clin and Exp.* (2019) 92:98–107. doi: 10.1016/j. metabol.2018.10.011

5. Piché ME, Poirier P, Lemieux I, Després JP. Overview of epidemiology and contribution of obesity and body fat distribution to cardiovascular disease: an update. *Prog Cardiovasc Dis.* (2018) 61(2):103–13. doi: 10.1016/j.pcad.2018.06.004

6. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. (2009) 53 (21):1925–32. doi: 10.1016/j.jacc.2008.12.068

7. Naqvi TZ, Lee MS. Carotid intima-media thickness and plaque in cardiovascular risk assessment. *JACC Cardiovascular Imaging.* (2014) 7 (10):1025–38. doi: 10.1016/j.jcmg.2013.11.014

8. Nezu T, Hosomi N, Aoki S, Matsumoto M. Carotid intima-Media thickness for atherosclerosis. J Atheroscler Thromb. (2016) 23(1):18-31. doi: 10.5551/jat.31989

9. Arterburn DE, Courcoulas AP. Bariatric surgery for obesity and metabolic conditions in adults. *BMJ (Clinical Research ed.* (2014) 349:g3961. doi: 10.1136/bmj.g3961

10. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. *N Engl J Med.* (2012) 366(17):1567–76. doi: 10.1056/NEJM0a1200225

11. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ (Clinical Research ed)*. (2009) 339:b2700. doi: 10.1136/bmj.b2700

12. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* (2010) 25(9):603–5. doi: 10.1007/s10654-010-9491-z

13. Altin C, Erol V, Aydin E, Yilmaz M, Tekindal MA, Sade LE, et al. Impact of weight loss on epicardial fat and carotid intima media thickness after laparoscopic sleeve gastrectomy: a prospective study. *Nut Metab and Cardiovasc Dis: NMCD.* (2018) 28(5):501–9. doi: 10.1016/j.numecd.2018.02.001

14. Baykara M, Yazar FM, Cengiz E, Bülbüloğlu E. Protective effects of laparoscopic sleeve gastrectomy on atherosclerotic and hemocytic parameters in obese patients. *Turk J Surg.* (2018) 34(3):169–77. doi: 10.5152/turkjsurg.2018.3939

15. Borzì AM, Buscemi C, Corleo D, Randazzo C, Rosafio G, Pantuso G, et al. Endothelial function in obese patients treated with bariatric surgery. *Diabetes Metab Syndr Obes: Targets Ther.* (2020) 13:247–56. doi: 10.2147/DMSO.S230684

16. Cekici Y, Kaya BC, Elkan H. The effect of laparoscopic sleeve gastrectomy on subclinical atherosclerosis in patients with severe obesity. *Obes Surg.* (2021) 31 (2):738–45. doi: 10.1007/s11695-020-05121-y

17. Chen J, Yu H, Chen L, Wu L, Hu B, Bao Y, et al. Effect of roux-en-Y gastric bypass on carotid intima-media thickness in Chinese obese patients with type 2 diabetes. *Surg for Obes and Relat Dis.* (2017) 13(9):1530–5. doi: 10.1016/j.soard. 2017.01.039

18. Cobeta P, Osorio A, Cuadrado-Ayuso M, García-Moreno F, Pestaña D, Galindo J, et al. Sleeve gastrectomy and gastric bypass decrease the carotid intima-Media thickness in obese men: association with weight loss, cardiovascular risk factors, and circulating testosterone. *Obes Surg.* (2020) 30 (3):851–9. doi: 10.1007/s11695-020-04405-7

19. Elitok A, Emet S, Bayramov F, Karaayvaz E, Türker F, Barbaros U, et al. Effect of bariatric surgery on flow-mediated dilation and carotid intima-media thickness in patients with morbid obesity: 1-year follow-up study. *Anatol J Cardiol.* (2020) 23(4):218–22. doi: 10.14744/AnatolJCardiol.2019.85249

20. Elkan H, Baş MM, Kaya B. Impact of laparoscopic sleeve gastrectomy on thrombomodulin concentration and early markers of atherosclerosis. *J Interv Cardiol.* (2022) 2022:6152571. doi: 10.1155/2022/6152571

21. García G, Bunout D, Mella J, Quiroga E, de la Maza MP, Cavada G, et al. Bariatric surgery decreases carotid intima-media thickness in obese subjects. *Nutr Hosp.* (2013) 28(4):1102–8. doi: 10.3305/nh.2013.28.4.6474

22. Gómez-Martin JM, Aracil E, Insenser M, de la Peña G, Lasunción MA, Galindo J, et al. Changes in soluble TWEAK concentrations, but not those in amyloid- $\beta$ (1-40), are associated with a decrease in carotid intima-Media thickness after bariatric surgery in obese women. *Obes Facts.* (2020) 13 (3):321–30. doi: 10.1159/000507087

23. Habib P, Scrocco JD, Terek M, Vanek V, Mikolich JR. Effects of bariatric surgery on inflammatory, functional and structural markers of coronary atherosclerosis. *Am J Cardiol.* (2009) 104(9):1251–5. doi: 10.1016/j.amjcard.2009.06.042

24. Jonker FHW, van Houten VAA, Wijngaarden LH, Klaassen RA, de Smet A, Niezen A, et al. Age-Related effects of bariatric surgery on early atherosclerosis and cardiovascular risk reduction. *Obes Surg.* (2018) 28(4):1040–6. doi: 10.1007/s11695-017-2962-5

25. Kaul A, Kumar A, Baksi A, Singla V, Aggarwal S, Gulati G, et al. Impact of bariatric surgery on carotid intima-medial thickness and cardiovascular risk: results of a prospective study. *Surg Endosc.* (2021) 35(11):6006–12. doi: 10.1007/ s00464-020-08088-0

26. Kaya BC, Elkan H. The impact of weight loss after laparoscopic sleeve gastrectomy on early markers of atherosclerotic vascular disease: a prospective study. *Kardiol Pol.* (2020) 78(7-8):674–80. doi: 10.33963/KP.15297

27. Nabavi N, Ghodsi A, Rostami R, Torshizian A, Jamialahmadi T, Jangjoo A, et al. Impact of bariatric surgery on carotid intima-Media thickness in patients with morbid obesity: a prospective study and review of the literature. *Obes Surg.* (2022) 32(5):1563–9. doi: 10.1007/s11695-022-05976-3

28. Salman MA, Salman AA, El Sherbiny M, Elkholy S, Youssef A, Labib S, et al. Changes of carotid intima-Media thickness after sleeve gastrectomy in high cardiovascular risk patients: a prospective study. *Obes Surg.* (2021) 31 (8):3541–7. doi: 10.1007/s11695-021-05419-5

29. Sarmento PL, Plavnik FL, Zanella MT, Pinto PE, Miranda RB, Ajzen SA. Association of carotid intima-media thickness and cardiovascular risk factors in women pre- and post-bariatric surgery. *Obes Surg.* (2009) 19(3):339–44. doi: 10. 1007/s11695-008-9783-5

30. Solmaz A, Arici S, Gulcicek OB, Yavuz E, Yigitbas H, Ercetin C, et al. Influence of bariatric surgery on carotid intima-Media thickness. *Bariatr Surg Pract Patient Care.* (2016) 11(2):56–60. doi: 10.1089/bari.2015.0046

31. Sturm W, Tschoner A, Engl J, Kaser S, Laimer M, Ciardi C, et al. Effect of bariatric surgery on both functional and structural measures of premature atherosclerosis. *Eur Heart J.* (2009) 30(16):2038–43. doi: 10.1093/eurheartj/ehp211

32. Tschoner A, Sturm W, Gelsinger C, Ress C, Laimer M, Engl J, et al. Longterm effects of weight loss after bariatric surgery on functional and structural markers of atherosclerosis. *Obesity (Silver Spring, Md)*. (2013) 21(10):1960–5. doi: 10.1002/oby.20357

33. Yavuz DG, Apaydin T, Imre E, Uygur MM, Yazici D. Skin autofluorescence and carotid intima-Media thickness evaluation following bariatric surgery in patients with severe obesity. *Obes Surg.* (2021) 31(3):1055–61. doi: 10.1007/ s11695-020-05077-z

34. Saleh MH, Bertolami MC, Assef JE, Taha MI, de Freitas Jr. W, Petisco AC, et al. Improvement of atherosclerotic markers in non-diabetic patients after bariatric surgery. *Obes Surg.* (2012) 22(11):1701–7. doi: 10.1007/s11695-012-0706-0

35. Yorulmaz G, Cilekar M, Bilge U, Akcan E, Akalin A. Carotid intima-media thickness and insulin resistance changes in patients who underwent sleeve gastrectomy: a prospective study. *Niger J Clin Pract.* (2016) 19(3):344–8. doi: 10. 4103/1119-3077.179280

36. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. *Circulation*. (2007) 115(4):459–67. doi: 10.1161/CIRCULATIONAHA.106.628875

37. Ciobârcă D, Cătoi AF, Copăescu C, Miere D, Crișan G. Bariatric surgery in obesity: effects on gut Microbiota and micronutrient Status. *Nutrients*. (2020) 12 (1):235. doi: 10.3390/nu12010235

38. Ying J, Dai S, Fu R, Hong J, Dai C, Jin Q. Effect of ursodeoxycholic acid on gallstone formation after bariatric surgery: an updated meta-analysis. *Obesity (Silver Spring, Md).* (2022) 30(6):1170–80. doi: 10.1002/oby.23427

39. Emami MR, Safabakhsh M, Khorshidi M, Moradi Moghaddam O, Mohammed SH, Zarezadeh M, et al. Effect of bariatric surgery on endogenous sex hormones and sex hormone-binding globulin levels: a systematic review and meta-analysis. *Surg for Obes and Relat Dis.* (2021) 17(9):1621–36. doi: 10.1016/j. soard.2021.05.003

40. Franco M, Bilal U, Orduñez P, Benet M, Morejón A, Caballero B, et al. Population-wide weight loss and regain in relation to diabetes burden and cardiovascular mortality in Cuba 1980-2010: repeated cross sectional surveys and ecological comparison of secular trends. *BMJ (Clinical Research ed).* (2013) 346:f1515. doi: 10.1136/bmj.f1515

41. Wolfe BM, Kvach E, Eckel RH. Treatment of obesity: weight loss and bariatric surgery. *Circ Res.* (2016) 118(11):1844–55. doi: 10.1161/CIRCRESAHA. 116.307591

42. Askarpour M, Khani D, Sheikhi A, Ghaedi E, Alizadeh S. Effect of bariatric surgery on Serum inflammatory factors of obese patients: a systematic review and meta-analysis. *Obes Surg.* (2019) 29(8):2631–47. doi: 10.1007/s11695-019-03926-0

43. Brown RM, Guerrero-Hreins E, Brown WA, le Roux CW, Sumithran P. Potential gut-brain mechanisms behind adverse mental health outcomes of bariatric surgery. *Nat Rev Endocrinol.* (2021) 17(9):549–59. doi: 10.1038/s41574-021-00520-2

44. le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. *Ann Surg.* (2006) 243(1):108–14. doi: 10.1097/01.sla.0000183349.16877.84

45. Lupoli R, Milone M, Di Minno A, Maietta P, Ambrosino P, Musella M, et al. Haemostatic and fibrinolytic changes in obese subjects undergoing bariatric surgery: the effect of different surgical procedures. *Blood Transfus.* (2015) 13(3):442–7. doi: 10.2450/2014.0183-14

46. Jamialahmadi T, Reiner Ž, Alidadi M, Almahmeed W, Kesharwani P, Al-Rasadi K, et al. Effect of bariatric surgery on intima Media thickness: a systematic review and meta-analysis. *J Clin Med.* (2022) 11(20):6056. doi: 10. 3390/jcm11206056

47. Hu Z, Sun J, Li R, Wang Z, Ding H, Zhu T, et al. A comprehensive comparison of LRYGB and LSG in obese patients including the effects on QoL, comorbidities, weight loss, and complications: a systematic review and meta-analysis. *Obes Surg.* (2020) 30(3):819–27. doi: 10.1007/s11695-019-04306-4

48. Gu L, Huang X, Li S, Mao D, Shen Z, Khadaroo PA, et al. A meta-analysis of the medium- and long-term effects of laparoscopic sleeve gastrectomy and

laparoscopic roux-en-Y gastric bypass. BMC Surg. (2020) 20(1):30. doi: 10.1186/s12893-020-00695-x

49. Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. (2015) 16 (7):581-606. doi: 10.1111/obr.12282

50. Knowlton AA, Lee AR. Estrogen and the cardiovascular system. *Pharmacol Ther.* (2012) 135(1):54–70. doi: 10.1016/j.pharmthera.2012.03.007

51. Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. *Biol Sex Differ*. (2017) 8(1):33. doi: 10.1186/s13293-017-0152-8